Conflict of interest: Dr Wu, Dr Weinstein, Dr Kormeili and Dr McCullough have no conflict of interest with the sponsor. Dr Kricorian is the Director of Medical Affairs at Valeant Pharmaceuticals International.
Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea
Article first published online: 14 SEP 2007
Clinical and Experimental Dermatology
Volume 32, Issue 6, pages 693–695, November 2007
How to Cite
Wu, J. J., Weinstein, G. D., Kricorian, G. J., Kormeili, T. and McCullough, J. L. (2007), Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. Clinical and Experimental Dermatology, 32: 693–695. doi: 10.1111/j.1365-2230.2007.02513.x
- Issue published online: 14 SEP 2007
- Article first published online: 14 SEP 2007
- Accepted for publication 9 April 2007
Many patients with rosacea are unable to tolerate extended treatment periods with topical agents because of the unusually high skin sensitivity that often accompanies rosacea. Kinetin (N6-furfuryladenine) is a plant cytokinin that reportedly helps restore skin barrier function and may be useful to ameliorate the signs and symptoms of rosacea. The purpose of this open-label study was to determine the tolerance and efficacy of twice-daily application of kinetin 0.1% lotion for improving the signs and symptoms of mild to moderate facial rosacea. Subjects applied kinetin 0.1% lotion twice daily to the face, with daily use of a sunscreen of sun protection factor 30. Subjects were evaluated at baseline and at 4-week intervals for 12 weeks to assess efficacy and tolerance. Results of this study suggest that kinetin 0.1% lotion is a well-tolerated moisturizing lotion option for subjects with mild to moderate inflammatory rosacea.